146 related articles for article (PubMed ID: 37423815)
21. Oncological safety and functional outcomes of testosterone replacement therapy in symptomatic adult-onset hypogonadal prostate cancer patients following robot-assisted radical prostatectomy.
Shahine H; Zanaty M; Zakaria AS; Nguyen DD; Couture F; Sadri I; Schwartz R; Arezki A; Elterman D; El-Hakim A; Zorn KC
World J Urol; 2021 Sep; 39(9):3223-3229. PubMed ID: 33034733
[TBL] [Abstract][Full Text] [Related]
22. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
23. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
24. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
25. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.
Leibowitz RL; Dorff TB; Tucker S; Symanowski J; Vogelzang NJ
BJU Int; 2010 May; 105(10):1397-401. PubMed ID: 19912179
[TBL] [Abstract][Full Text] [Related]
26. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
[TBL] [Abstract][Full Text] [Related]
27. Is testosterone treatment good for the prostate? Study of safety during long-term treatment.
Feneley MR; Carruthers M
J Sex Med; 2012 Aug; 9(8):2138-49. PubMed ID: 22672563
[TBL] [Abstract][Full Text] [Related]
28. Testosterone supplementation does not worsen lower urinary tract symptoms.
Pearl JA; Berhanu D; François N; Masson P; Zargaroff S; Cashy J; McVary KT
J Urol; 2013 Nov; 190(5):1828-33. PubMed ID: 23764078
[TBL] [Abstract][Full Text] [Related]
29. [Testosterone replacement therapy for hypogonadism in men with prostate cancer].
Jensen CF; Fode M; Østergren P; Sønksen J
Ugeskr Laeger; 2017 Feb; 179(9):. PubMed ID: 28263152
[TBL] [Abstract][Full Text] [Related]
30. Testosterone replacement therapy after primary treatment for prostate cancer.
Agarwal PK; Oefelein MG
J Urol; 2005 Feb; 173(2):533-6. PubMed ID: 15643240
[TBL] [Abstract][Full Text] [Related]
31. [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].
Rinnab L; Gust K; Hautmann RE; Küfer R
Urologe A; 2009 May; 48(5):516-22. PubMed ID: 19296069
[TBL] [Abstract][Full Text] [Related]
32. Untreated hypogonadism and testosterone replacement therapy in hypogonadal men are associated with a decreased risk of subsequent prostate cancer: a population-based study.
Asanad K; Horns JJ; Driggs N; Samplaski MK; Hotaling JM
Int J Impot Res; 2024 Jan; ():. PubMed ID: 38177194
[TBL] [Abstract][Full Text] [Related]
33. Testosterone Therapy on Active Surveillance and Following Definitive Treatment for Prostate Cancer.
Golla V; Kaplan AL
Curr Urol Rep; 2017 Jul; 18(7):49. PubMed ID: 28589395
[TBL] [Abstract][Full Text] [Related]
34. Testosterone replacement therapy is associated with an increased risk of urolithiasis.
McClintock TR; Valovska MI; Kwon NK; Cole AP; Jiang W; Kathrins MN; Bhojani N; Haleblian GE; Koehlmoos T; Haider AH; Basaria S; Trinh QD
World J Urol; 2019 Dec; 37(12):2737-2746. PubMed ID: 30903351
[TBL] [Abstract][Full Text] [Related]
35. Validating the total cancer location density metric for stratifying patients with low-risk localized prostate cancer at higher risk of grade group reclassification while on active surveillance.
Tan GH; Deniffel D; Finelli A; Wettstein M; Ahmad A; Zlotta A; Fleshner N; Hamilton R; Kulkarni G; Nason G; Ajib K; Herrera-Caceres J; Chandrasekar T; Perlis N
Urol Oncol; 2023 Mar; 41(3):146.e23-146.e28. PubMed ID: 36639336
[TBL] [Abstract][Full Text] [Related]
36. To treat or not to treat with testosterone replacement therapy: a contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer.
Kava BR
Curr Urol Rep; 2014 Jul; 15(7):422. PubMed ID: 24832199
[TBL] [Abstract][Full Text] [Related]
37. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
38. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract][Full Text] [Related]
39. Testosterone replacement therapy following radical prostatectomy.
Khera M; Grober ED; Najari B; Colen JS; Mohamed O; Lamb DJ; Lipshultz LI
J Sex Med; 2009 Apr; 6(4):1165-1170. PubMed ID: 19207277
[TBL] [Abstract][Full Text] [Related]
40. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
